Patent challenger Bass shrugs off Celgene's attack on his short-selling motives
14 August 2015
Money makes the world go round--the patent world, that is. That's the word from hedge funder Kyle Bass, who has been targeting drug patents he calls "low quality," and shorting pharma stocks along the way.
What does Google's corporate shuffle mean for its biotech ambitions?
14 August 2015
Google ($GOOG) is divvying up its composite parts, becoming, depending on whom you ask, the new Berkshire Hathaway, the next General Electric or something heretofore never seen. But the move could have mixed implications for Google's nascent but growing life sciences empire--including the high-profile, secretive biotech Calico --as shuffling things around could expose such moonshot projects to the pitchforks of profit-hungry investors.
Then and Now: How Prescription Drug Prices Fall Significantly Over Time
13 August 2015
Prescription drug prices fall significantly over time because the marketplace is unlike any other part of the U.S. health care system.
How slow can Big Pharma go in emerging markets?
13 August 2015
Industry watchers have pointed to a slowdown in pharma's emerging markets growth as a worrying sign for companies that have been heavily targeting developing nations while the U.S. and European markets stagnate. But just how slow has the growth become?
FDA makes its first approval of a 3-D printed drug
13 August 2015
For the first time, the FDA has approved a drug produced using a 3D printer. Aprecia Pharmaceuticals picked up the approval and distinction of being first past the post when the FDA gave the all-clear to its adjunctive therapy for the treatment of epilepsy.
The Future of Clinical Pathways
13 August 2015
Utilization of clinical pathways, in which an individual’s treatment follows a defined protocol, can help ensure patients receive the best possible care based on the most recent scientific data. However, clinical pathways can institutionalize a “cookie cutter” approach instead of personalized medicine, as well as limit treatment options in order to cut costs. So, which of these will be the future for clinical pathways?
A new normal in China for pharmaceutical industry as reforms accumulate?
12 August 2015
Second-quarter earnings from nearly all multinationals showed a drop in business in China from double-digit paces in recent years, blamed on tough tender and reimbursement policies and domestic competition as well as an economic slowdown.
Study: Device industry suffers from first-mover disadvantage due to FDA regs
12 August 2015
The first high-risk medical device in a given category--such as a coronary stent or transaortic valve replacement--takes 34% longer to be approved than a follow-on version from a competitor, finds a Harvard Business School study.
Drug Delivery Systems for Biopharmaceuticals
12 August 2015
Industry experts discuss key considerations in the development of a drug-delivery device for a biologic drug.
11 August 2015
Epic Sciences announced today the publication of its research in the Journal of Circulating Biomarkers validating the company's no cell left behind™ platform. The data published demonstrate reproducible and linear assay performance in CTC enumeration as well as additional utility in downstream molecular characterization of single CTCs, including protein biomarker analysis and single cell genomics.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024